TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01562002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell with Amniotic Membrane Transplant
Description: Single stem cell expansion in amniotic membrane transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell with Amniotic Membrane Transplant
Description: Single stem cell expansion in amniotic membrane transplant
Study: NCT03753282

Intervention type: OTHER
Intervention: questionnaires for patient reported outcome
Description: questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication
Study: NCT03753282

Intervention type: OTHER
Intervention: questionnaires for patient reported outcome
Description: questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication

Intervention type: OTHER
Intervention: questionnaire for course of the disease
Description: questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions

Intervention type: OTHER
Intervention: questionnaire for course of the disease
Description: questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions
Study: NCT05051332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (CartiLife®)
Description: CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture Surgery
Description: Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
Study: NCT04291235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Management Pathway
Description: Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
Study: NCT01061437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACx14
Description: Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACMx5
Description: Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAx5/PCMx5
Description: Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
Study: NCT02767635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox-Epic
Description: injected 20 units of Botox into lateral epicondyle in Botox-Epic group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox-Tend
Description: injected 20 units of Botox into tender point of muscles in Botox-Tend group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide (Steroid)
Description: injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
Study: NCT02991235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PRJ212
Description: 6 capsules of study product will be taken daily and orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules of study product will be taken daily and orally.
Study: NCT01024647

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 200 mg every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 400 mg every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 400 mg every 4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: certolizumab pegol
Description: certolizumab pegol 400 mg every 2 weeks
Study: NCT03636360

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light
Description: 15 hours of light exposure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light
Description: 15 hours of light exposure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light
Description: 15 hours of light exposure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light
Description: 15 hours of light exposure
Study: NCT00451217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
Study: NCT00953914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
Study: NCT00924599

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle education (English & Spanish)
Description: The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
Study: NCT00984139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Intramuscular, one dose.
Study: NCT02715700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg oral tablet once per day.
Study: NCT02062424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIPI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIPI
Study: NCT02780024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,
Study: NCT00538044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
Study: NCT01950273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Description: BI695500, once a week for 4 weeks (4 administrations in total)
Study: NCT06394856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques
Description: rotator cuff tears with modified versus classic double row suture bridge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques
Description: rotator cuff tears with modified versus classic double row suture bridge
Study: NCT00258349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT03499691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 500 medium cut-off dialyzer
Description: The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
Study: NCT02224027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: proceal laryngeal mask airway
Description: In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal tube
Description: In tracheal tube group, tracheal tube is intubated by novices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: In i-gel group, i-gel is inserted by novices.
Study: NCT03940274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking training
Description: Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
Study: NCT02085668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation (Symplicity™)
Description: Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
Study: NCT01892709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Study: NCT02210286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magtein
Study: NCT00559780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance training (3/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the quadriceps muscle
Description: 12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard rehabilitation
Description: 12 weeks of standard physiotherapy exercises (1h/day)
Study: NCT00774527

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Cyclophosphamide-fludarabine-anti thymocyte globulin
Description: * Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.
Study: NCT02395237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: : Amaryl® M IR 2/1000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: : Amaryl® M IR 2/1000
Study: NCT00348595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revlimid
Description: one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
Study: NCT01950273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: MabThera, once a week for 4 weeks (4 administrations in total)
Study: NCT02611310

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study.
Study: NCT03497494

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 cm away from the pylorus edge
Description: 2 cm away from the pylorus edge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 cm away from the pylorus edge
Description: 2 cm away from the pylorus edge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 cm away from the pylorus edge
Description: 4 cm away from the pylorus edge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 cm away from the pylorus edge
Description: 4 cm away from the pylorus edge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cm away from the pylorus edge
Description: 6 cm away from the pylorus edge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cm away from the pylorus edge
Description: 6 cm away from the pylorus edge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRYGB
Description: laparoscopic Roux-en-Y gastric bypass
Study: NCT04568356

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Direct Antigen Tests for COVID-19
Description: Rapid Antigen diagnostic device performance comparative to RT-PCR
Study: NCT03475719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUG186-B and HUG186-D
Description: Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUG186
Description: Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
Study: NCT00872430

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Klein Laxative Tea
Description: The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Klein Laxative Tea
Description: The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
Study: NCT03229616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Etoposide was administered at 15 mg/kg/day on days -3 to -2.
Study: NCT02847819

Intervention type: DEVICE
Intervention: airway ultrasound for vocal cords movement assessment.
Description: Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
Study: NCT02182583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ba253MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba253BINEB
Study: NCT03675308

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous injection
Study: NCT01517490

Intervention type: OTHER
Intervention: Insulin pump
Description: Insulin pump therapy

Intervention type: OTHER
Intervention: Insulin pump
Description: Insulin pump therapy

Intervention type: OTHER
Intervention: Multiple daily insulin injections
Description: Multiple daily insulin injections

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Pre-operative weight loss and bariatric surgery.
Study: NCT00393744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pristinamycin
Description: 50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: 50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
Study: NCT01517490

Intervention type: OTHER
Intervention: Medical therapy for type 2 diabetes
Description: Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
Study: NCT03930914

Intervention type: DEVICE
Group type: OTHER
Intervention: Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device
Description: Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm

Intervention type: DEVICE
Group type: OTHER
Intervention: Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device
Description: Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
Study: NCT04020159

Intervention type: OTHER
Intervention: Patient Registry
Description: No intervention/treatment
Study: NCT03758638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating & Active Living Taught at Home
Description: PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an \~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
Study: NCT02656745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Smoking Cessation Solution
Description: The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program.
Study: NCT03338205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 mg/kg ketamine bolus IV
Study: NCT03915080

Intervention type: DRUG
Group type: OTHER
Intervention: Oktokog alpha
Description: adjusting dose and dose interval according to MyPKFIT
Study: NCT06056986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multimodal ultrasound
Description: Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
Study: NCT03698617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction of general anesthesia
Study: NCT02880969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: answering questionnaires
Study: NCT02096809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One week loading of Bone Anchored Hearing Aid (BAHA)
Description: Patients in this arm will be fitted with the BAHA one week after surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Baha BI300/BA400 Implant System
Study: NCT02868619

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI
Description: functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI
Description: functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety

Intervention type: OTHER
Group type: OTHER
Intervention: ADO-BEDS scale
Description: Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria